Cagrilintide 10mg

Product Overview

Cagrilintide 10mg is a long-acting amylin analog designed to mimic the natural hormone amylin, which works alongside insulin to regulate appetite, slow gastric emptying, and promote feelings of fullness. It’s being studied for its potential role in weight management, glucose regulation, and enhanced metabolic health—often in combination with GLP-1 receptor agonists like semaglutide or liraglutide for synergistic effects. Its prolonged activity and high receptor affinity make it a novel approach in peptide research focused on energy balance and appetite suppression.

Key Benefits

• Promotes satiety and reduces food intake
• Supports weight management and fat loss
• Slows gastric emptying, improving post-meal glucose control
• Enhances insulin sensitivity and metabolic stability
• May complement GLP-1 analogs for enhanced outcomes
• Long half-life allows for convenient dosing frequency

Mechanism of Action

Cagrilintide activates amylin and calcitonin receptors in the brain, particularly in the area postrema and hypothalamus, which regulate hunger and energy expenditure. By mimicking the actions of endogenous amylin, it reduces food intake, slows digestion, and enhances glucose control, contributing to improved metabolic efficiency and body composition outcomes in research contexts.

(Note: For research use only; not for human or veterinary consumption.)

Storage & Stability

• Store dry powder at –20 °C
• Once reconstituted, refrigerate at 2–8 °C
• Avoid repeated freeze-thaw cycles

Summary

Cagrilintide 10mg represents a cutting-edge advancement in appetite and energy balance research, complementing GLP-1 agonists and other metabolic peptides. Its unique profile makes it a strong candidate for continued exploration in the fields of obesity management, metabolic health, and glucose regulation.

All information provided is for informational and research reference purposes only and should not be interpreted as medical advice. NordWellness makes no claims regarding therapeutic use or outcomes.